One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Search from 250 M+ research papersSearch from 250 M+ research papershttps://doi.org/10.1182/blood-2018-99-110563
Copy DOI Journal: Blood |  Publication Date: Nov 29, 2018 |
 Citations: 3 |
Affiliation: University of Bologna, Charles University, University Hospital Hradec Králové, Essen University Hospital, Takeda (United States), University of Debrecen, Saitama Medical University, Samsung Medical Center, Memorial Sloan Kettering Cancer Center, Institut Català d'Oncologia, Hackensack University Medical Center, Odense University Hospital, Universitätsmedizin Göttingen, China Medical University Hospital, China Medical University, Northwestern University, BC Cancer Agency, University of British Columbia, Freeman Hospital, Manchester Academic Health Science Centre, The Christie NHS Foundation Trust, Washington University in St. Louis, Seagen (United States), Calvary Mater Newcastle Hospital, Columbia University Irving Medical Center, University of Washington Medical Center, The University of Texas MD Anderson Cancer Center, Stanford Blood Center, Spedali Civili di Brescia, Tokyo National Hospital, Centre Hospitalier Universitaire de LilleThe ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
